Clinuvel identifies potential new target for Scenesse
25 August, 2010 by David BinningMelbourne biotech Clinuvel announced today that it plans to conduct clinical trials of its UV protection drug Scenesse as a treatment for the skin pigmentation disorder vitiligo.
Cellestis reports FY net profit up 26 percent
24 August, 2010 by Staff WritersMelbourne biotech Cellestis this week announced a full year net profit of $10.22 million, following strong growth in all of the company’s major markets.
Market report: ASX down amid renewed global concerns while election hangs on a knife edge
21 August, 2010 by David BinningThe Australian stock market finished down today amid renewed concerns about the pace of the global economic recovery and as local investors await the outcome of tomorrow’s federal election, which has become too close to call.
CSL announces profit dip and $900m share buyback
18 August, 2010 by Staff WritersCSL, Australia’s biggest biotech and the world’s second largest producer of plasma blood products, today reported an eight percent dip in full year net profit to $1.05 billion, as a rising Australian dollar dented overseas revenues.
2Fr solid-state wireless pressure catheter
17 August, 2010 by Staff WritersMillar Instruments and Telemetry Research have set a new standard for telemetry research by developing the TRM53P.
Aspen to buy Sigma Pharmaceuticals' drug division for $900m
17 August, 2010 by David BinningTroubled drug developer and healthcare provider Sigma Pharmaceuticals finally put an end to months of speculation today declaring that it would recommend shareholders accept an offer from Aspen Pharmacare to buy its pharmaceuticals business for $900 million.
Mesoblast progressing towards Phase 3 trial bone marrow trial in US
16 August, 2010 by Staff WritersRegenerative medicine specialists Mesoblast today announced that it has provided market guidance to the FDA regarding its Phase 3 bone marrow transplantation program, which it hopes will create more options for patients as well as a reduction in incidences of graft-versus-host disease (GVHD).
Market report: ASX holds firm despite global gloom
13 August, 2010 by David BinningThe Australian stock market ended slightly up today as miners helped the bourse to resist to drag of poor performers such as Telstra, although it wasn’t enough to continue the run of five consecutive weekly gains.
BioTech Capital throws in the towel
13 August, 2010 by Staff WritersBioTech Capital One, of the highest profile Australian biotech investment funds announced on Thursday that it will no longer pursue new opportunities in the sector and will liquidate its current investment portfolio, returning the proceeds to shareholders.
AQL and Farmacule merger complete
13 August, 2010 by Staff WritersThe merger of private therapeutic protein and biofuels company Farmacule and publicly-listed industrial algae specialists AquaCarotene (AQL) was completed yesterday creating a promising new Australian biotechnology company producing biofuels and plant-made compounds for use in the medical research, nutraceutical and industrial markets.
Patrys appoints Dr Marie Roskrow as new CMO and president
12 August, 2010 by Staff WritersMelbourne biotech Patrys has appointed renowned medical academic Dr Marie Roskrow as its Chief Medical Officer and President.
Cochlear reports record full year results
10 August, 2010 by Staff WritersCochlear released its full year results today reporting a 19 percent increase in net profit to $155.2 million on the back of record total revenues of $784.8 million.
Feature: Automating the personalised medicine revolution
10 August, 2010 by Fiona WylieProcessing large numbers of samples rapidly is going to be crucial if the vision of personalised medicine is ever going to become a reality.
Market report: ASX chalks up five-week winning streak
06 August, 2010 by David BinningThe Australian stock market finished the week up for the fifth week in a row today as investor’s maintained their run of confidence despite weaker-than-expected jobs and retail sales data out of the US overnight.
Study links full-fat dairy with reduced heart attack risk
05 August, 2010 by Staff WritersIn yet another case of conventional medical wisdom being turned on its head, researchers at the Queensland Institute of Medical Research (QIMR) have completed a study showing that people who consume full-fat dairy may have a lower risk of heart attack.
